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 ABSTRACT 
 
Objective – The reported effects of treating cerebral cavernous malformations (CCMs) by 
neurosurgical excision or stereotactic radiosurgery are imprecise and vary between studies. 
Methods – We searched Ovid Medline, EMBASE and The Cochrane Library for peer-reviewed 
publications of cohort studies describing outcomes of treating 20 or more patients with CCM with 
at least 80% completeness of follow-up. Two reviewers extracted data to quantify the incidence of 
a composite outcome (death, non-fatal intracranial haemorrhage, or new/worse persistent focal 
neurological deficit) after CCM treatment. We explored associations between summary measures 
of study characteristics and outcome using Poisson meta-regression analyses. 
 
Results – We included 63 cohorts, involving 3,424 patients. The incidence of the composite 
outcome was 6.6 (95% confidence interval [CI] 5.7-7.5) per 100 person-years after neurosurgical 
excision (median follow-up 3.3 years) and 5.4 (95% CI 4.5-6.4) after stereotactic radiosurgery 
(median follow-up 4.1 years). After neurosurgical excision the incidence of the composite outcome 
increased with every percent point increase in patients with brainstem CCM (risk ratio [RR] 1.03, 
95%CI 1.01-1.05), and decreased with each more recent study mid-year (RR 0.91, 95% CI 0.85-
0.98) and each percent point increase in patients presenting with haemorrhage (RR 0.98, 95% CI 
0.96-1.00). We did not find significant associations in studies of stereotactic radiosurgery. 
 
Conclusions – The reported risks of CCM treatment (and the lower risks of neurosurgical excision 
over time, from recently bled CCMs, and for CCM outside the brainstem) compare favourably with 
the risks of recurrent haemorrhage from CCM. Long-term effects, especially important for 
stereotactic radiosurgery, are unknown. 
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INTRODUCTION 
 
Patients with cerebral cavernous malformations (CCMs) are at risk of epileptic seizures,1 
intracranial haemorrhage (ICH), and non-haemorrhagic focal neurological deficit (FND).2 CCM 
treatment with neurosurgical excision or stereotactic radiosurgery (SRS) aims to decrease the risks 
of these outcomes, but treatment also confers a risk of these same outcomes.3;4 
 
CCM treatments have not been compared with each other or with conservative management in a 
randomised controlled trial and none of the individual comparative observational (non-
randomised) studies has reliably demonstrated ‘dramatic’ beneficial effects of treatment.5 
Consequently, decisions about CCM treatment rest upon indirect comparisons of lifetime 
estimates of the untreated course of CCM versus the estimated risks and benefits of treatment. 
 
In the absence of data from randomised trials, data on the effects of treatment from case series 
can help in the decision about whether to treat a patient with a CCM by estimating overall risks 
and by identifying groups either at higher chance of a good outcome or at lower risk of a poor 
outcome. However, most reported series have been small and individually underpowered to 
determine cohort, patient, or CCM characteristics that influence treatment outcome.3;4 
 
Therefore, we set out firstly to identify all published original case series in order to quantify the 
risks of CCM treatment with neurosurgical excision or SRS with precision, and secondly to use 
meta-regression analysis of these studies to examine determinants of the outcome of treatment. 
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METHODS 
 
Protocol 
We conducted this systematic review according to a pre-defined protocol (see online 
supplemental appendix 1) and report our findings according to the Preferred Reporting Items for 
Systematic Review and Meta-analyses (PRISMA) guidelines.6  
 
Search strategy and selection criteria 
We used comprehensive electronic strategies (see online supplemental appendix 2) to search Ovid 
Medline, EMBASE and The Cochrane Library on July 31th 2012 for articles meeting our pre-defined 
eligibility criteria. We crosschecked the bibliographies of included articles to identify additional 
studies until we did not identify further studies. One reviewer (MHFP) screened titles, abstracts 
and full text for eligible studies (see online supplementary table 1). We sought original articles 
published in peer-reviewed journals of cohort studies reporting the arbitrarily chosen number of 
20 or more patients of any age with CCM confirmed by magnetic resonance imaging [MRI] or 
pathological examination in all patients,7;8 who underwent treatment with neurosurgical excision 
or SRS, and in whom the occurrences of death, ICH, or FND were quantified per patient per 
treatment modality. If the completeness of the cohort's entire follow-up was both described and 
was more than 80% complete, we included outcomes reported in the entire duration of follow-up. 
If follow-up was not described, we included cohorts if we could extract outcomes that occurred 
within 30 days of treatment. If a subset of patients in a publication met the eligibility criteria, we 
included them if we were able to extract outcomes per treatment modality for at least 90% of this 
subset of patients. Where multiple publications arose from the same cohort, we included the 
study with the largest sample size. We included eligible studies published in any language apart 
from Korean (for which we had no translator). We excluded studies if the proportion of patients in 
the study population with extra-cerebral or extra-cranial cavernous malformations exceeded 10%. 
 
Data extraction 
Two reviewers (MHFP and one of four others) independently extracted the relevant data from the 
included studies (see online supplementary table 2), and any discrepancies were resolved in 
consensus meetings by MHFP, CJMK and RA-SS. We collected data on study design, patient 
demographics, CCM characteristics, presenting symptoms, and type of CCM treatment. We 
extracted data on whether each series reported consecutive or selected patients, the method of 
follow-up (prospective, retrospective, prospective patient collection with retrospective follow-up, 
or unknown), and whether outcome assessment was done by an independent observer and 
blinded to treatment. We quantified the occurrence of our composite outcome (death, non-fatal 
ICH, and non-fatal new or worse non-haemorrhagic persistent FND after CCM treatment, if they 
were attributed to the CCM or its treatment) during follow-up. If authors did not describe the total 
duration of follow-up or if more than 20% of patients were lost to follow-up, we extracted 
outcome data on the period within 30 days of treatment only. We used authors’ descriptions of 
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the occurrence of ICH, because most studies were published before standards for reporting of 
CCM haemorrhage were published.2 
 
Statistical analysis 
We separated our analyses of cohorts according to whether they reported the effects of 
neurosurgical excision or SRS. We quantified the occurrence of outcomes during the total person-
years of follow-up described, or by multiplying the median or mean follow-up period by the total 
number of treated patients. We calculated outcome event incidence rates and 95% confidence 
intervals (CIs) per 100 person-years. We pre-specified the following characteristics of the included 
cohorts as the baseline covariates of interest: cohort mid-year, average age of the patients at the 
time of treatment, proportion of female patients, proportion of patients with a brainstem CCM, 
proportion of patients with a prior symptomatic ICH from the CCM, and the proportion of children. 
We assessed differences in proportions of these characteristics between studies describing 
neurosurgical excision and those describing SRS with Mann Whitney U tests with a p-value <0.05 
indicating significant differences. We performed Poisson meta-regression analyses of cohort 
characteristics on the incidence of the composite outcome. For the assessment of the overall 
incidence rate, we used the intercept of a Poisson model without covariates. We restricted our 
analyses to covariates that were reported in at least five cohorts. We assessed the relationship of 
cohort characteristics to each outcome by calculating adjusted rate ratios (RRs) with 
corresponding 95% CIs, adjusting for four pre-specified cohort characteristics because of their 
known or assumed influence on our chosen outcome events: age, sex, proportion of brainstem 
CCM, and proportion of patients who had presented with haemorrhage. We expressed adjusted 
RRs per 1% increase in the proportion of patients with a cohort characteristic or per 1-year 
increase in age or mid-year (defined as the middle of the time frame of the years in which 
treatment took place), such that a 1% change in the characteristic in cohorts resulted in a (RR-1 x 
100)% change in the cohorts’ outcome. We intended to perform sensitivity analyses restricted to 
high-quality studies (defined as being an inception cohort, (a cohort with patients identified at a 
uniform time point in the disease), having a prospective design, and using independent outcome 
assessment blind to treatment)), if at least five studies met these criteria. To assess consistency of 
effects across cohorts, we used the I-squared (I2) statistic.9 
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RESULTS 
 
After screening 7,415 publications we identified 62 eligible studies reporting on 63 cohorts (see 
online supplemental figure 1) including 3,424 treated CCM patients with a total of 10,029 patient-
years of follow-up. Forty-nine cohorts involving 2,684 patients reported on neurosurgery (6707 
patient years of follow up) and 14 cohorts involving 740 patients reporting SRS (3322 patient years 
of follow up), in 11 using Gamma Knife10-20 and in three using linear accelerator.13;21;22  
 
Characteristics of the included studies 
Fifteen (24%) cohorts explicitly described identifying consecutive patients. 54 (86%) cohorts were 
from single centres and the others were multicentre. 33 (52%) cohorts were from Europe, 18 
(29%) from Asia, 11 (18%) from North America, and one (2%) from South America. Five (8%) were 
prospective, 38 (60%) retrospective, two (3%) identified patients prospectively but followed them 
up retrospectively, and 18 (29%) did not specify their study design. 14 cohorts did not describe 
mean nor median duration of follow-up, but only outcome within 30 days of treatment. In none of 
the 63 cohorts was the outcome assessment performed by an independent person, blinded to 
treatment. In the 14 cohorts reporting SRS outcome, the median margin dose was 16 (range 12-
25) Gy and the median maximum dose (reported in 11 cohorts) was 27 (range 16-33) Gy. We 
found statistically significant differences between the proportions of patients in neurosurgical and 
SRS cohorts in CCM size, CCM site, and the frequency of multiple CCMs (Table 1). 
 
Composite outcome event rates 
The numbers of cohorts reporting on the different outcome events are given in Table 2 (and online 
supplementary table 3). 32 cohorts reported on the composite outcome (21 neurosurgery cohorts, 
and 11 stereotactic radiosurgery cohorts). The composite outcome incidence was 6.1 (95% CI 5.4-
6.8) per 100 person-years for all cohorts combined (I2=81%), 6.6 (95% CI 5.7-7.5) after 
neurosurgical excision (I2=85%), and 5.4 (95% CI 4.5-6.4) after SRS (I2=63%).  
 
Associations with the composite outcome 
In 22 cohorts with data on brainstem CCM, age, sex and presentation with ICH, the incidence of 
the composite outcome increased with every 1% increase in the proportion of patients with 
brainstem CCMs (adjusted RR 1.02, 95% CI 1.01-1.03). In 14 cohorts, after neurosurgical excision 
the adjusted RR was 1.03, 95%CI 1.01-1.05 and in 8 cohorts after SRS the adjusted RR was 1.03, 
95%CI 0.95-1.11 (Table 3). The incidence of the composite outcome after neurosurgical excision 
decreased for every one-year increase in study mid-year (adjusted RR 0.91, 95% CI 0.85-0.98), 
which differed from the association after SRS (pinteraction=0.003). The incidence of the composite 
outcome after neurosurgical excision decreased with every 1% increase in the proportion of 
patients presenting with haemorrhage (adjusted RR 0.98, 95%CI 0.96-1.00). We did not find any 
statistically significant associations with the composite outcome after SRS. 
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Table 1: Characteristics of the included cohorts 
 
 Overall (n=63) Neurosurgery (n=49) Stereotactic radiosurgery (n=14) 
Study characteristics Cohorts (%)
a 
Patients Median (range) Cohorts (%)
a 
Patients Median (range) Cohorts (%)
a 
Patients Median (range) 
Patients treated 63 (100) 3424 39 (11
b
-260)
 
49 (100) 2684 39 (20-260) 14 (100) 740 36 (11
b
-125) 
Duration of follow-up, y 63 (100) 3424 2.3 (0.1-8.1) 49 (100) 2684 1.4 (0.1-8.1) 14 (100) 740 4.1 (0.8-6.5) 
Mid-year, y 59 (94) 3228 1996 (1983-2009) 46 (94) 2572 1997 (1983-2009) 13 (93) 656 1996 (1990-2001) 
Age, y 51 (81) 2916 36 (8-52) 39 (80) 2323 35 (8-52) 12 (86) 593 37 (24-41) 
Female, % 52 (83) 2808 50 (29-68) 40 (82) 2215 50 (29-68) 12 (86) 593 47 (35-62)  
Multiple CCMs, % 39 (62) 2358 10 (0-25) 31 (63) 1814 9 (0-25)* 8 (57) 544 15 (10-20)* 
Children, % 17 (27) 836 0 (0-100) 15 (31) 814 0 (0-100) 2 (14) 22 18 (0-36) 
Size, mm 23 (37) 1506 18 (12-27) 18 (37) 1259 19 (15-27)* 5 (36) 247 14 (12-20)* 
CCM associated with DVA, % 19 (30) 960 8 (0-35) 14 (29) 744 11 (0-35) 5 (36) 216 5 (2-27) 
CCM location       
Total supratentorial, % 57 (91) 3095 73 (0-100) 45 (92) 2489 83 (0-100)* 12 (86) 606 39 (0-86)* 
Lobar, % 53 (84) 2838 60 (0-100) 42 (86) 2252 75 (0-100)* 11 (79) 586 18 (0-64)* 
Basal ganglia and thalamus, 
% 
53 (84) 2838 3 (0-42) 42 (86) 2252 0 (0-42)** 11 (79) 586 18 (0-33)** 
Total infratentorial, % 57 (91) 3095 24 (0-100) 45 (92) 2489 16 (0-100)* 12 (86) 606 61 (12-100)* 
Brainstem, % 56 (89) 3057 15 (0-100) 44 (90) 2451 7 (0-100)* 12 (86) 606 46 (2-100)* 
Cerebellum, % 56 (89) 3057 0 (0-32) 44 (90) 2451 0 (0-32) 12 (86) 606 5 (0-18) 
Presented with ICH, % 44 (70) 2377 71 (0-100) 32 (65) 1825 47 (0-100) 12 (86) 552 90 (26-100) 
Presented asymptomatic, % 50 (79) 2813 0 (0-23) 37 (76) 2165 0 (0-23) 13 (93) 648 0 (0-11) 
CCM, cerebral cavernous malformation; DVA, developmental venous anomaly; ICH, intracranial haemorrhage.
 a 
The percentage is the number of cohorts reporting on a 
specific study characteristic divided by the total number of cohorts. 
b
 One cohort of 22 patients
 
treated using stereotactic radiosurgery was separated in 11 patients 
treated using gamma knife radiosurgery and 11 patients treated using linear accelerator. *P<0.05 and **P<0.01, indicating significant differences in the median proportion 
of this study characteristic between cohorts describing neurosurgical treatment and cohorts describing treatment by stereotactic radiosurgery. 
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Table 2: Incidence of the composite outcome (and its constituent events) according to the modality of cerebral cavernous malformation 
treatment 
 
 Cohorts (%)  Patients Total number of 
outcome events 
/ Person-years 
Median number 
per cohort (range) 
Outcome event incidence 
(95% CI) per 100 person-
years 
All cohorts Follow-up, person-years 63 (100) 3424 - 72 (1.7-1020) - 
Composite outcome* 32 (51) 1568 313 / 5169 3 (0-108) 6.1 (5.4-6.8) 
 Deaths attributable to CCM or  treatment 63 (100) 3424 28 / 10029 0 (0-4) 0.3 (0.2-0.4) 
 Deaths not attributed to CCM or
 treatment 
61 (97) 3228 18 / 9348 0 (0-4) 0.2 (0.1-0.3) 
 Symptomatic ICH 43 (68) 2465 160 / 8331 1 (0-32) 1.9 (1.6-2.2) 
 Persistent FND 42 (67) 2123 201 / 6290 2 (0-82) 3.2 (2.8-3.7) 
Neurosurgery 
cohorts 
Follow-up, person-years 49 (100) 2684 - 48 (1.7-1020) - 
Composite outcome 21 (43) 1100 198 / 3021 2 (0-108) 6.6 (5.7-7.5) 
 Deaths attributable to CCM or  treatment 49 (100) 2684 18 / 6707 0 (0-4) 0.3 (0.2-0.4) 
 Deaths not attributed to CCM or 
 treatment 
48 (98) 2613 7 / 6701 0 (0-4) 0.1 (0.05-0.2) 
 Symptomatic ICH 29 (59) 1725 53 / 5008 1 (0-22) 1.1 (0.8-1.4) 
 Persistent FND 31 (63) 1655 176 / 4143 2 (0-82) 4.3 (3.7-4.9) 
Stereotactic 
radiosurgery 
cohorts 
Follow-up, person-years 14 (100) 740 - 160 (24.9-675) - 
Composite outcome 11 (79) 468 115 / 2147 5 (1-35) 5.4 (4.5-6.4) 
 Deaths attributable to CCM or treatment 14 (100) 740 10 / 3322 0 (0-2) 0.3 (0.2-0.6) 
 Deaths not attributed to CCM or
 treatment 
13 (93) 615 11 / 2647 0 (0-3) 0.4 (0.2-0.8) 
 Symptomatic ICH 14 (100) 740 107 / 3322 5 (0-32) 3.2 (2.7-3.9) 
 Persistent FND 11 (79) 468 25 / 2147 2 (0-6) 1.2 (0.8-1.7) 
CCM, cerebral cavernous malformation; ICH, intracranial haemorrhage; FND, focal neurological deficit; CI, confidence interval. 
*Composite outcome consisted of death, non-fatal symptomatic ICH or non-fatal new or worse non-haemorrhagic persistent FND attributed to CCM or its 
treatment. 
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Table 3: Associations between study characteristics and the incidence of the composite outcome (death, non-fatal intracranial haemorrhage or 
new or worsened persistent focal neurological deficit attributed to CCM or its treatment). 
 
 All cohorts (n = 63) Neurosurgery (n = 49) Stereotactic Radiosurgery (n = 14) 
Study characteristic Cohorts Events RR (95% CI) Cohorts Events RR (95% CI) Cohorts Events RR (95% CI) 
Mid-year, y  *  13 178 0.91 (0.85-0.98) 8 62 1.03 (0.96-1.11) 
Age, y
 
 22 244 1.01 (0.98-1.05) 14 182 0.99 (0.95-1.03) 8 62 0.96 (0.65-1.41) 
Female, % 22 244 1.01 (0.99-1.03) 14 182 1.00 (0.98-1.02) 8 62 1.03 (0.87-1.21) 
Brainstem, % 22 244 1.02 (1.01-1.03) 14 182 1.03 (1.01-1.05) 8 62 1.03 (0.95-1.11) 
ICH as presenting symptom, % 22 244 1.00 (0.99-1.01) 14 182 0.98 (0.96-1.00) 8 62 1.04 (0.96-1.13) 
Children, % 8 125 1.03 (0.98-1.09) 6 122 1.08 (0.98-1.21) 2 3 Not estimable 
Abbreviations: ICH, intracranial haemorrhage; RR, rate ratio; CI, confidence interval. 
All analyses are adjusted for patient age, sex, proportion of brainstem CCM, and proportion of patients presenting with haemorrhage, unless stated otherwise. The RRs 
are expressed per 1% increase in the proportion of patients with a study characteristic or per 1-year increase in age or mid-year.
 
* We did not analyse the effect of mid-year on the composite outcome in all cohorts together because there was a significant interaction between mid-year and 
treatment modality (p=0.003). 
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Sensitivity analyses 
We were not able to perform sensitivity analyses with high-quality studies, because we only 
identified three studies with all of our required characteristics, which was below our threshold for 
performing these analyses. 
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DISCUSSION 
 
We found that after neurosurgical excision or SRS the incidence of death, non-fatal symptomatic 
ICH or non-fatal new persistent FND attributed to CCM or its treatment is around 6 per 100 
person-years. For neurosurgical excision outcomes have improved over time, the risks are lower in 
patients presenting with haemorrhage and higher in those with brainstem CCM. For SRS we could 
not detect associations with outcome. Increasing patient age, within the confines of the ages at 
which patients have been reported to be treated, does not appear to affect the risks of treatment. 
The period of follow up of the studies included in the review was relatively short, and the number 
of high quality studies was too small to perform separate analyses restricted to high quality 
studies. 
 
Our literature search was extensive, comprehensive, and was only influenced by study quality and 
suitability for this analysis. By using all suitable published studies of CCM treatment outcome, we 
have been able to identify risk factors for an unfavourable course that could not be investigated in 
smaller individual cohorts. We used a variety of statistical techniques to account for the variation 
in reporting follow-up in individual cohorts (to maximise their inclusion); the inclusion of outcomes 
within only 30 days in 14 studies that did not report the total or average duration of follow-up may 
have slightly elevated these risks. Unfortunately, only three of the included studies fulfilled our 
criteria for high quality studies; none of the included studies performed outcome assessment 
using an independent observer, and most studies did not report methods and durations of follow-
up clearly. Duration of follow up was relatively short in comparison to the duration over which 
patients may expect benefit from treatment (Table 1), indicating the need for longer term follow-
up in all studies reporting the effects of neurosurgical excision and SRS. Unfortunately, data on 
whether resections had been complete or partial could not be analysed as they were not provided 
in the majority of the included studies. Functional outcome after treatment was reported in 27 
cohorts, either on a bespoke scale (7 cohorts) or by using a generic functional outcome scale. Five 
generic outcome scales were used to quantify functional outcome in 20 cohorts, so it was 
inappropriate to pool them and there were insufficient cohorts per treatment modality to 
examine associations with outcome on any one generic scale. Reporting of seizures after 
treatment was insufficient to enable us to examine influences on them reliably, as others have 
confirmed,23;24 although some predictors of seizure-freedom have been identified by others.25 
 
The overall risks of adverse events after neurosurgical excision or SRS may help to guide patient 
management by informing an indirect comparison of treatment risk versus the estimated risks of 
CCM events during their untreated clinical course in the short term (although the balance of risks 
in the long term remains uncertain).26;27 The overall ~6% risk of death or non-fatal stroke after 
both forms of treatment over 2-3 years of follow-up appears to compare unfavourably with the 
risk of first-ever ICH from a CCM that has never bled (2.4% over 5 years), regardless of the CCM 
location. However, the short term risks of treatment appear to compare favourably with natural 
history of recurrent ICH (29.5% over 5 years, all CCM locations combined). The associations that 
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we have found provide reassurance about the reported safety of neurosurgical excision in people 
who have recently bled from a CCM, in particular if the CCM is outside the brainstem. However, 
we have confirmed that brainstem CCMs are the most hazardous to treat with neurosurgical 
excision, but that this treatment has become safer over recent years (including for brainstem 
CCMs28-35), likely due to increasing surgical experience, technical developments and improved 
electrophysiological monitoring. Nevertheless, it remains challenging to select individual patients 
for excision of brainstem CCM based on its location and accessibility, the patient’s clinical status 
and expected rate of bleeding,36 and this dilemma would be best addressed in a randomised 
controlled trial. The available data did not reveal statistically significant associations between 
study-level patient or CCM characteristics and outcome after SRS, precluding statements about 
associations between CCM location and SRS outcome to help guide the use of SRS. Although the 
overall incidence of adverse effects after SRS was similar to neurosurgical excision, there are few 
data about the safety and long-term effects of SRS, which reinforces the need for the use of SRS 
for CCM to be restricted to research studies with adequate follow-up to capture the delayed 
effects of SRS. 
 
Our findings have implications for future research. The lack of high quality studies with long-term 
follow up stresses the need for prospective cohort studies with long term follow up and 
standardized and independent assessment of functional outcome to assess the effects of 
treatment. Ideally, such cohorts should include a randomised comparison of treatment versus 
conservative management, or comparison of treatment modalities. Standardised international 
prospective registries and randomised controlled trials could help determine which treatment 
strategies are most effective, and for whom. 
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